Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.71 |
| ▸ | FAAH | O00519 | 4/20 | 0.68 |
| ▸ | NAAA | Q02083 | 1/20 | 0.67 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.61 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.60 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22047271 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL20996896 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL27360833 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL31315579 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL8154588 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL24812541 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL26003367 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL19249062 | 0.98 | CASP2 (0.68) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL19248862 | 0.98 | CASP2 (0.68) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL114457 | 0.96 | FAAH (0.68) | CASP2FAAHNAAADNM1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188020-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | ACUITAS THERAPEUTICS INC (CA) | 2025-06-12 | — | — | US | disclosed |
| US-12129223-B2 | Lipids for use in lipid nanoparticle formulations | Acuitas Therapeutics, Inc. (CA) | 2024-10-29 | — | — | US | disclosed |
| EP-4448485-A2 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2024-10-23 | — | — | EP | disclosed |
| CN-118647600-A | Lipids for lipid nanoparticle formulations | 爱康泰生治疗公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| WO-2023114943-A2 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114943-A2 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | PHOSPHO1, SGMS1, NPC1 | CASP2 2856/4885FAAH 1559/4885NAAA 2563/4885 |
| US-20250188020-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | PHOSPHO1, SGMS1, NPC1 | CASP2 2856/4885FAAH 1559/4885NAAA 2563/4885 |
| US-12129223-B2 | Lipids for use in lipid nanoparticle formulations | PHOSPHO1, SGMS1, NPC1 | CASP2 2856/4885FAAH 1559/4885NAAA 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.